Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishen capsule is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of cardiovascular conditions such as atherosclerosis, chest pain (angina pectoris), and dyslipidemia, particularly those characterized by the "Qi deficiency and blood stasis" syndrome in TCM theory. Developed as a hospital preparation by the Department of Pharmacy at Anzhen Hospital of Capital Medical University, it is typically composed of herbal extracts including *Astragalus membranaceus* (Huangqi), *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and *Dalbergia odorifera* (Jiangxiang). The capsule is designed to tonify Qi, promote blood circulation, and resolve stasis. Clinical research has demonstrated its potential to reduce systemic inflammation (lowering markers like hs-CRP and IL-6), improve vascular endothelial function, and modulate lipid metabolism, often when used as an adjunct to statin therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qishen capsule.